90 related articles for article (PubMed ID: 18827566)
1. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein.
Hall PD; Beagle KL; Garrett-Mayer E; Frankel AE
Anticancer Drugs; 2008 Nov; 19(10):1007-11. PubMed ID: 18827566
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
[TBL] [Abstract][Full Text] [Related]
4. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity.
Hall PD; Razzouk BI; Willoughby TE; McLean TW; Frankel AE
J Pediatr Hematol Oncol; 2002 Oct; 24(7):521-6. PubMed ID: 12368687
[TBL] [Abstract][Full Text] [Related]
5. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy.
Hall PD; Sinha D; Frankel AE
Cancer Immunol Immunother; 2006 Aug; 55(8):928-32. PubMed ID: 16645883
[TBL] [Abstract][Full Text] [Related]
6. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
7. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
8. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
Williams MD; Rostovtsev A; Narla RK; Uckun FM
Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
[TBL] [Abstract][Full Text] [Related]
9. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins.
Jedema I; Barge RM; Frankel AE; Willemze R; Falkenburg JH
Exp Hematol; 2004 Feb; 32(2):188-94. PubMed ID: 15102480
[TBL] [Abstract][Full Text] [Related]
11. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
[TBL] [Abstract][Full Text] [Related]
12. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
[TBL] [Abstract][Full Text] [Related]
14. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
[TBL] [Abstract][Full Text] [Related]
15. Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection.
Shantha Kumara HM; Kirman I; Feingold D; Cekic V; Nasar A; Arnell T; Balik E; Hoffman A; Baxter R; Conte S; Whelan RL
Eur J Surg Oncol; 2009 Mar; 35(3):295-301. PubMed ID: 18782657
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.
Frankel A; Liu JS; Rizzieri D; Hogge D
Leuk Lymphoma; 2008 Mar; 49(3):543-53. PubMed ID: 18297533
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
Hogge DE; Feuring-Buske M; Gerhard B; Frankel AE
Leuk Res; 2004 Nov; 28(11):1221-6. PubMed ID: 15380349
[TBL] [Abstract][Full Text] [Related]
18. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells.
Westcott MM; Abi-Habib RJ; Cohen KA; Willingham MC; Liu S; Bugge TH; Leppla SH; Frankel AE
Mol Cancer Ther; 2004 Dec; 3(12):1681-9. PubMed ID: 15634662
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF.
Rozemuller H; Terpstra W; Rombouts EJ; Lawler M; Byrne C; FitzGerald DJ; Kreitman RJ; Wielenga JJ; Löwenberg B; Touw IP; Hagenbeek A; Martens AC
Leukemia; 1998 Dec; 12(12):1962-70. PubMed ID: 9844926
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein.
Rozemuller H; Rombouts EJ; Touw IP; FitzGerald DJ; Kreitman RJ; Pastan I; Hagenbeek A; Martens AC
Br J Haematol; 1997 Sep; 98(4):952-9. PubMed ID: 9326195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
